Article in Journal of Alzheimer's disease : JAD, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Mark A BernardCenter for Cognitive Neurology, Department of Neurology, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0003-2523-9782
Allal BoutajangoutCenter for Cognitive Neurology, Department of Neurology, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0002-9582-5675
Ludovic DebureCenter for Cognitive Neurology, Department of Neurology, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0009-0003-4898-3122
Wajiha AhmedCenter for Cognitive Neurology, Department of Neurology, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0009-0007-8121-0307
Anthony Q BriggsCenter for Cognitive Neurology, Department of Neurology, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0002-9459-5214
Carolina Boza-CalvoAlzheimer's Disease Research Center, NYU Grossman School of Medicine, New York, NY, USA.
Alok VedvyasCenter for Cognitive Neurology, Department of Neurology, NYU Grossman School of Medicine, New York, NY, USA.
Karyn MarshCenter for Cognitive Neurology, Department of Neurology, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0009-0003-9057-1551
Omonigho M BubuCenter for Cognitive Neurology, Department of Neurology, NYU Grossman School of Medicine, New York, NY, USA.
Ricardo S OsorioAlzheimer's Disease Research Center, NYU Grossman School of Medicine, New York, NY, USA.
Thomas WisniewskiCenter for Cognitive Neurology, Department of Neurology, NYU Grossman School of Medicine, New York, NY, USA.
Arjun V MasurkarCenter for Cognitive Neurology, Department of Neurology, NYU Grossman School of Medicine, New York, NY, USA.
Funding
Research Education ComponentP30AG066512 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Mary Sherman Mittelman · 2020 to 2026
$28.4M
Transgenic/Behavior CoreP01AG060882 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI UEBERHEIDE, BEATRIX MAGDALENA · 2020 to 2024
$12.0M
Using a Health Disparity Research Framework to examine mechanisms linking Obstructive Sleep Apnea with higher Alzheimer’s disease risk in older Blacks/African-AmericansR01AG082278 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI OMONIGHO A MICHAEL Bubu · 2023 to 2026
$6.9M
Slow wave sleep (SWS) and the effect of African ancestry on amyloid burden, a longitudinal studyR01AG056531 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI JEAN-LOUIS, GIRARDIN, OSORIO, RICARDO S · 2018 to 2022
$6.7M
Sleep Aging and Risk for Alzheimer's disease-Resubmission-1R01AG056031 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI OSORIO, RICARDO S · 2018 to 2022
$4.4M
Treatment of OSA on sleep-dependent memory and blood biomarkers in blacksRF1AG083975 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI OMONIGHO A MICHAEL Bubu, Korey Kam · 2023 to 2026
$4.2M
Brain Effects of Lifetime Racial/Ethnic Discrimination on the LC-NE Function and the Risk for Alzheimer's DiseaseR01AG072644 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DING, YU-SHIN, OSORIO, RICARDO S · 2021 to 2024
$3.3M
The mediating role of Slow Wave Sleep and Vascular Risk Factors on Alzheimer Disease related disparity between African-Americans and non-Hispanic WhitesK23AG068534 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BUBU, OMONIGHO A MICHAEL · 2021 to 2025
$958k
Locus-coeruleus function in normal elderly and AD risk (LEAD)R21AG067549 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DING, YU-SHIN, OSORIO, RICARDO S · 2020 to 2021
Anxiety is highly prevalent in Alzheimer's disease (AD), correlating with cerebrospinal fluid/positron emission tomography biomarkers and disease progression. Relationships to plasma biomarkers are unclear. Herein, we compare levels of plasma biomarkers in research participants with and without anxiety at cognitively normal, mild cognitive impairment, and AD dementia stages. We observed significantly higher plasma tau/amyloid-β
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The relationship between anxiety and levels of Alzheimer's disease plasma biomarkers. · full record | OpenQuestion